Sign in

CIK 0001737287 · Non-accelerated filer<br>Smaller reporting company

Allogene Therapeutics, Inc.

Sign in to watch
Ticker
ALLO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
operating
EIN
823562771
Phone
(650) 457-2700
Business address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
  1. 4 Open-market buy Director bought 15,000 shares at $12.60 ($189,000)
  2. 4 Open-market buy Director bought 155,039 shares at $12.60 ($1,953,491)
  3. 8-K Event Material agreement · Other events
  4. 10-Q Report Quarterly Report
  5. 8-K Event Results of operations
  6. CT ORDER Other Confidential Order
  7. 8-K Event Other events
  8. 4 Open-market sale EVP of R&D and CMO sold 11,507 shares at $24.35 ($280,185)
  9. 3 Insider Initial Statement of Ownership
  10. 4 Open-market sale General Counsel sold 5,000 shares at $24.77 ($123,845)
  11. SC 13D/A Stake Beneficial Ownership Report
  12. 4 Open-market sale Director sold 5,000 shares at $25.54 ($127,700)
  13. 4 Open-market sale Director sold 10,000 shares at an average $23.47 ($234,700)
  14. 4 Open-market sale General Counsel sold 5,000 shares at $21.00 ($104,994)
  15. 10-Q Report Quarterly Report
  16. 8-K Event Results of operations
  17. 4 Grant or award Director acquired 19,362 shares (grant or award)
  18. 4 Derivatives Options or other derivatives
  19. 3 Insider Initial Statement of Ownership
  20. 3 Insider Initial Statement of Ownership

Page 19 of 30 · 587 filings